Sanofi, Maze license agreement would contribute to Sanofi's monopoly power, US FTC says in administrative complaint
MLex Summary: Sanofi and Maze Therapeutics' agreement under which Sanofi would license the rights to Maze's MZE001 Pompe disease therapy should be blocked because it would "eliminate the nascent threat MZE001...To view the full article, register now.
Already a subscriber? Click here to view full article